Resona Asset Management Co. Ltd. Purchases 1,734 Shares of IQVIA Holdings Inc. $IQV

Resona Asset Management Co. Ltd. lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.0% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 60,143 shares of the medical research company’s stock after purchasing an additional 1,734 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in IQVIA were worth $9,477,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of IQV. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after acquiring an additional 131 shares in the last quarter. AllSquare Wealth Management LLC purchased a new position in IQVIA in the 1st quarter worth $33,000. Trust Co. of Toledo NA OH bought a new stake in IQVIA in the second quarter worth $39,000. J.Safra Asset Management Corp boosted its position in IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after buying an additional 169 shares during the period. Finally, NewSquare Capital LLC grew its stake in shares of IQVIA by 185.3% during the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after buying an additional 189 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent research reports. William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. Barclays boosted their price objective on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. TD Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating and raised their target price for the stock from $206.00 to $215.00 in a report on Monday, November 3rd. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $239.94.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Down 0.2%

Shares of IQVIA stock opened at $210.50 on Friday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $225.00. The company has a market cap of $35.85 billion, a P/E ratio of 28.88, a PEG ratio of 2.35 and a beta of 1.34. The company’s fifty day simple moving average is $199.38 and its two-hundred day simple moving average is $176.30.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the previous year, the firm posted $2.84 EPS. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.